
Opinion|Videos|August 6, 2024
Current and Emerging Treatment Options for Neurofibromatosis Type 1 Related Plexiform Neurofibroma
Author(s)Kaleb H. Yohay, MD
A healthcare expert examines Mirdametinib as an investigational treatment for NF1-PN, focusing on its potential role in managing the condition in adolescents and adults who have moved beyond pediatric care.
Advertisement
Episodes in this series

- Mirdametinib is currently being investigated as a treatment option for adolescents and adults who have transitioned out of adolescent care who are living with NF1-PN. Can you comment on the recent phase II data?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Insights on Vibrance-2 Study Results of Alixorexton in Narcolepsy Type 2: Richard K. Bogan, MD, FCCP, FAASM
2
FDA Clears Investigational New Drug Application for Remyelinating Agent PTD802 in Multiple Sclerosis
3
Pipeline Review: Alzheimer Disease Therapies by Mechanism of Action
4
FDA and EMA Accepts Regulatory Applications for Cemdisiran in Generalized Myasthenia Gravis
5


















